Press releases
- Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases
- Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split
- Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
- Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting
- Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
- Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress
- Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
More ▼
Key statistics
On Tuesday, Atara Biotherapeutics Inc (AT20:BER) closed at 8.85, 86.22% above the 52 week low of 4.75 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 0.00 |
Low | 0.00 |
Bid | -- |
Offer | -- |
Previous close | 8.85 |
Average volume | 194.99 |
---|---|
Shares outstanding | 4.90m |
Free float | 4.46m |
P/E (TTM) | -- |
Market cap | 40.36m USD |
EPS (TTM) | -52.93 USD |
Data delayed at least 15 minutes, as of Jun 18 2024 19:30 BST.
More ▼